The Business Research Company’s report on the Polymyalgia Rheumatica Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the polymyalgia rheumatica market?
The rise in demand for personalized medicine is expected to propel the growth of the polymyalgia rheumatica market going forward. Personalized medicine is medical treatment tailored to an individual’s genetic profile, lifestyle, and specific health conditions for more effective outcomes. The demand for personalized medicine is driven by advancements in genetic research, growing patient expectations for tailored treatments, and improvements in diagnostic technologies. Genetic research provided a deeper understanding of individual genetic variations, allowing for more customized treatments targeting specific genetic markers. Personalized medicine can help select drugs that are most likely effective based on the patient’s characteristics, leading to a more effective and safer treatment plan. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the rise of personalized medicine is driving the growth of the polymyalgia rheumatica market.
Growth In Telemedicine Services Fueling The Expansion Of The Market Due To Increasing Convenience And Remote Care
The growth in telemedicine services is expected to propel the growth of the polymyalgia rheumatica market going forward. Telemedicine services use digital communication technologies, such as video calls, phone calls, and online messaging, to provide remote medical consultations, diagnoses, treatment, and follow-up care to patients without the need for in-person visits. The growth in telemedicine services is due to increasing demand for convenient healthcare options and cost-effective healthcare solutions. Patients increasingly seek convenience, especially for non-urgent consultations, which telemedicine offers by eliminating the need for in-person visits. The growth of telemedicine services supports polymyalgia rheumatica (PMR) by enabling remote monitoring of symptoms, medication management, and regular follow-ups, which are crucial for managing chronic pain and inflammation. For instance, in November 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, in 2022-23, people using telehealth consultation was 87.7%, which reached 89.2% in 2023-24. Therefore, the growth in telemedicine services is driving the growth of the polymyalgia rheumatica market.
Access Your Free Sample of the Global Polymyalgia Rheumatica Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp
How has the polymyalgia rheumatica market size evolved, and what are the latest forecasts for its expansion?
The polymyalgia rheumatica market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to rising awareness among healthcare practitioners, rising use of corticosteroids, growth in specialty clinics, the introduction of biologic therapies, and rising healthcare budgets.
The polymyalgia rheumatica market size is expected to see strong growth in the next few years. It will grow to $1.73 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the growing adoption of biologics, expansion of precision medicine, accelerated drug approvals, broader reimbursements, and expansion of clinical trials. Major trends in the forecast period include the development of combination therapies, advancements in personalized medicine, the development of precision medicine, the integration of electronic health records, and advancements in biomarkers.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22103&type=smp
Which major companies dominate the polymyalgia rheumatica market?
Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women’s Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital
What trends will shape the future of the poly(adp-ribose) polymerase (parp) inhibitors market?
Major companies operating in the polymyalgia rheumatica market are focusing on developing advanced drugs, such as interleukin-6 (IL-6) receptor blockers, to provide more targeted and effective treatment options. Interleukin-6 (IL-6) receptor blockers are biological drugs that inhibit IL-6, a key pro-inflammatory cytokine in autoimmune diseases. By blocking IL-6, these treatments reduce inflammation and improve symptoms, enhancing the quality of life for PMR patients. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare company, announced the Food and Drug Administration (FDA) approved Kevzara (sarilumab) for treating polymyalgia rheumatica (PMR) in adults who haven’t responded well to corticosteroids or can’t tolerate tapering off them. Kevzara, the first and only biologic approved for this condition, works by inhibiting IL-6-mediated signaling. The approval was based on a study where 28.3% of patients on sarilumab achieved sustained remission at week 52, compared to 10.3% on placebo2. Kevzara is administered via subcutaneous injection once every two weeks and is also approved for treating moderately to severely active rheumatoid arthritis. Sanofi’s stock (SNY) is currently priced at $54.13 on the NASDAQ.
Which region dominates the polymyalgia rheumatica market, and what factors contribute to its leadership?
Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report
How is the polymyalgia rheumatica market segmented, and which segment holds the largest share?
The polymyalgia rheumatica market covered in this report is segmented –
1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Type: Adult, Geriatric, Periatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib
3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine
4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103
What defines the structure and scope of the polymyalgia rheumatica market?
Polymyalgia rheumatica (PMR) is an inflammatory disorder that primarily affects older adults, causing muscle pain and stiffness, particularly in the shoulders, hips, and neck. It is characterized by aching and swelling in the muscles around the shoulders and hips, leading to difficulty in movement and daily activities.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
